Shares of Biocon Ltd. were on a tailspin on the Bombay Stock Exchange in early trade on July 10 after a pre-approval inspection by the French regulator, ANSM, flagged compliance deficiencies at its Bommasandra site in Bangalore for three biosimilars - pegfilgrastim (Fulphila), trastuzumab (Ogivri) and insulin glargine (Semglee).
The ANSM inspection raised 35 deficiencies, including 11 “major” ones such as those pertaining to OOS (out-of-specification) results management, cross...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

